Serum IgM antibodies contribute to high levels of opsonophagocytic activities in toddlers immunized with a single dose of the 9-valent pneumococcal conjugate vaccine

Clinical and Vaccine Immunology

Volumn 19, Issue 10, 2012, Pages 1618-1623

  Simell, Birgit ^a,c   Nurkka, Anu ^a   Ekström, Nina ^a   Givon Lavi, Noga ^b   Käyhty, Helena ^a   Dagan, Ron ^b  

^a NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^b BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^c UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; PNEUMOCOCCUS VACCINE;

ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; ASSAY; CHILD; ENZYME IMMUNOASSAY; HUMAN; IMMUNOGENICITY; MULTIPLEXED OPSONOPHAGOCYTOSIS ASSAY; NORMAL HUMAN; OPSONIZATION; PRESCHOOL CHILD; PRIORITY JOURNAL; SEROTYPE; SINGLE DRUG DOSE; TODDLER;

ANTIBODIES, BACTERIAL; CHILD, PRESCHOOL; HUMANS; IMMUNIZATION; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INFANT; OPSONIN PROTEINS; PHAGOCYTOSIS; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; POLYSACCHARIDES, BACTERIAL; STREPTOCOCCUS PNEUMONIAE; VACCINES, CONJUGATE;

EID: 84867249667     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00248-12     Document Type: Article

References (28)

1. Advisory Committee on Immunization Practices. Licensure of a 13-valent pneumococcal conjugate vaccine (PCV13) and recommendations for use among children. MMWR Morb. Mortal. Wkly. Rep. 59:258-261.
2. Bagget HC, et al. 2006. Immunologic response to Haemophilus influenzae type b (Hib) conjugate vaccine and risk factors for carriage among Hib carriers and noncarriers in southwestern Alaska. Clin. Vaccine Immunol. 13:620-626.
3. Burton RL, Nahm MH. 2006. Development and validation of a fourfold multiplexed opsonization assay (MOPA4) for pneumococcal antibodies. Clin. Vaccine Immunol. 13:1004-1009. (Pubitemid 44518968)
4. CDC. 1995. Progress toward elimination of Haemophilus influenzae disease among infants and children. MMWR Morb. Mortal. Wkly. 44:545-550.
5. Center KJ. 2007. Prevenar vaccination: review of the global data, 2006. Vaccine 25:3085-3089. (Pubitemid 46482738)
6. Clutterbuck EA, et al. 2012. Serotype-specific and age-dependent generation of pneumococcal polysaccharide-specific memory B-cell and antibody responses to immunization with a pneumococcal conjugate vaccine. Clin. Vaccine Immunol. 15:182-193. (Pubitemid 352025528)
7. Dagan R, et al. 2005. Serum serotype-specific pneumococcal anticapsular immunoglobulin g concentrations after immunization with a 9-valent conjugate pneumococcal vaccine correlate with nasopharyngeal acquisition of pneumococcus. J. Infect. Dis. 192:367-376. (Pubitemid 41023114)
8. Dagan R, et al. 2002. Reduction of nasopharyngeal carriage of Streptococcus pneumoniae after administration of a 9-valent pneumococcal conjugate vaccine to toddlers attending day care centers. J. Infect. Dis. 185:927-936. (Pubitemid 34274436)
9. Dentinger CM, et al. 2006. Immunogenicity and reactogenicity to Haemophilus influenzae type b (Hib) conjugate vaccine among rural Alaska adults. Hum. Vaccin. 2:24-28. (Pubitemid 43667662)
10. Fearon DT, Locksley RM. 1996. The instructive role of innate immunity in the acquired immune response. Science 272:50-53.
11. Hausdorff WP, Dagan R, Beckers F, Schuerman L. 2009. Estimating the direct impact of new conjugate vaccines against invasive pneumococcal disease. Vaccine 27:7257-7269.
12. Janeway CA, Travers P, Walport MJ, Shlomchik MJ. 2005. The humoral immune response, p 367-408. In Janeway CA, Travers P, Walport MJ, Shlomchik MJ (ed), Immunobiology: the immune system in health and disease, 6th ed. Garland Science Publishing, New York, NY.
13. Nieminen T, Kayhty H, Leroy O, Eskola J. 1999. Pneumococcal conjugate vaccination in toddlers: mucosal antibody response measured as circulating antibody-secreting cells and as salivary antibodies. Pediatr. Infect. Dis. J. 18:764-772. (Pubitemid 29428530)
14. Peltola H, Kilpi T, Anttila M. 1992. Rapid disappearance of Haemophilus influenzae type b meningitis after routine childhood immunisation with conjugate vaccines. Lancet 340:592-594.
15. Riedmann EM. 2012. News. Hum. Vaccin. Immunother. 8:2.
16. Romero-Steiner S, et al. 1999. Reduction in functional antibody activity against Streptococcus pneumoniae in vaccinated elderly individuals highly correlates with decreased IgG antibody avidity. Clin. Infect. Dis. 29:281-288. (Pubitemid 29380185)
17. Rothlein R, Springer TA. 1985. Complement receptor type three-dependent degradation of opsonized erythrocytes by mouse macrophages. J. Immunol. 135:2668-2672. (Pubitemid 16215866)
18. Ruben FL, Uhrin M. 1985. Specific immunoglobulin-class antibody responses in the elderly before and after 14-valent pneumococcal vaccine. J. Infect. Dis. 151:845-849. (Pubitemid 15094601)
19. Schenkein JG, Park S, Nahm M. 2008. Pneumococcal vaccination in older adults induces antibodies with low opsonic capacity and reduced antibody potency. Vaccine 26:5521-5526.
20. Sigurdardottir ST, et al. 1997. Immune responses of infants vaccinated with serotype 6B pneumococcal polysaccharide conjugated with tetanus toxoid. Pediatr. Infect. Dis. J. 16:667-674. (Pubitemid 27300705)
21. Silfverdal SA, et al. 2011. Anamnestic immune response in 3-to 4-year-old children previously immunized with 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine as 2-dose or 3-dose priming and a booster dose in the first year of life. Pediatr. Infect. Dis. J. 30:e155-163.
22. Simell B, Lahdenkari M, Reunanen A, Kayhty H, Vakevainen M. 2008. Effects of ageing and gender on naturally acquired antibodies to pneumococcal capsular polysaccharides and virulence-associated proteins. Clin. Vaccine Immunol. 15:1391-1397.
23. Simell B, et al. 2010. Aging reduces the functionality of anti-pneumococcal antibodies and the killing of Streptococcus pneumoniae by neutrophil phagocytosis. Vaccine 29:1929-1934.
24. Tsai TF, et al. 2006. Early appearance of bactericidal antibodies after polysaccharide challenge of toddlers primed with a group C meningococcal conjugate vaccine: what is its role in the maintenance of protection? Clin. Vaccine Immunol. 13:854-861. (Pubitemid 44409623)
25. Walport MJ. 2001. Complement. First of two parts. N. Engl. J. Med. 344:1058-1066.
26. WHO. 2009. Recommendations to assure the quality, safety and efficacy of pneumococcal conjugate vaccines: proposed replacement of TRS 927, Annex 2, ECBS, 19 to 23 October 2009. WHO Technical Report Series. World Health Organization, Geneva, Switzerland. http://www.who.int /biologicals/publications/trs/areas/ vaccines/pneumo/en/index.html.
27. Vidarsson G, et al. 1998. Isotypes and opsonophagocytosis of pneumococcus type 6B antibodies elicited in infants and adults by an experimental pneumococcus type 6B-tetanus toxoid vaccine. Infect. Immun. 66:2866-2870. (Pubitemid 28261797)
28. Wuorimaa T, et al. 2001. Tolerability and immunogenicity of an eleven-valent pneumococcal conjugate vaccine in healthy toddlers. Pediatr. Infect. Dis. J. 20:272-277. (Pubitemid 32240266)